BRAIN Biotech AG (XTRA:BNN) will look acquisitions. Brain Biotech aims to double product revenue in the mid-term and to position itself among the top ten in the global enzyme market. “We will continue to focus on multiple niche markets within the food and beverage, healthcare and environmental markets.

These attractive segments represent addressable markets well above EUR 1 billion (USD 1.08 billion),” Brain Biotech's Chief Executive Officer Adriaan Moelker committed in the statement. “We are now aiming for strong organic growth and additional bolt-on acquisitions in the coming years,” the CEO added.